Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines : an international cardiology survey
© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology..
AIMS: In symptomatic patients with heart failure and reduced ejection fraction (HFrEF), recent international guidelines recommend initiating four major therapeutic classes rather than sequential initiation. It remains unclear how this change in guidelines is perceived by practicing cardiologists versus heart failure (HF) specialists.
METHODS AND RESULTS: An independent academic web-based survey was designed by a group of HF specialists and posted by email and through various social networks to a broad community of cardiologists worldwide 1 year after the publication of the latest European HF guidelines. Overall, 615 cardiologists (38 [32-47] years old, 63% male) completed the survey, of which 58% were working in a university hospital and 26% were HF specialists. The threshold to define HFrEF was ≤40% for 61% of the physicians. Preferred drug prescription for the sequential approach was angiotensin-converting enzyme inhibitors or angiotensin receptor-neprilysin inhibitors first (74%), beta-blockers second (55%), mineralocorticoid receptor antagonists third (52%), and sodium-glucose cotransporter 2 inhibitors (53%) fourth. Eighty-four percent of participants felt that starting all four classes was feasible within the initial hospitalization, and 58% felt that titration is less important than introducing a new class. Age, status in training, and specialization in HF field were the principal characteristics that significantly impacted the answers.
CONCLUSION: In a broad international cardiology community, the 'historical approach' to HFrEF therapies remains the preferred sequencing approach. However, accelerated introduction and uptitration are also major treatment goals. Strategy trials in treatment guidance are needed to further change practices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
European journal of heart failure - 25(2023), 2 vom: 21. Feb., Seite 213-222 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 23.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ejhf.2743 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349176019 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349176019 | ||
| 003 | DE-627 | ||
| 005 | 20231226042011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.2743 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349176019 | ||
| 035 | |a (NLM)36404398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fauvel, Charles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines |b an international cardiology survey |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 23.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. | ||
| 520 | |a AIMS: In symptomatic patients with heart failure and reduced ejection fraction (HFrEF), recent international guidelines recommend initiating four major therapeutic classes rather than sequential initiation. It remains unclear how this change in guidelines is perceived by practicing cardiologists versus heart failure (HF) specialists | ||
| 520 | |a METHODS AND RESULTS: An independent academic web-based survey was designed by a group of HF specialists and posted by email and through various social networks to a broad community of cardiologists worldwide 1 year after the publication of the latest European HF guidelines. Overall, 615 cardiologists (38 [32-47] years old, 63% male) completed the survey, of which 58% were working in a university hospital and 26% were HF specialists. The threshold to define HFrEF was ≤40% for 61% of the physicians. Preferred drug prescription for the sequential approach was angiotensin-converting enzyme inhibitors or angiotensin receptor-neprilysin inhibitors first (74%), beta-blockers second (55%), mineralocorticoid receptor antagonists third (52%), and sodium-glucose cotransporter 2 inhibitors (53%) fourth. Eighty-four percent of participants felt that starting all four classes was feasible within the initial hospitalization, and 58% felt that titration is less important than introducing a new class. Age, status in training, and specialization in HF field were the principal characteristics that significantly impacted the answers | ||
| 520 | |a CONCLUSION: In a broad international cardiology community, the 'historical approach' to HFrEF therapies remains the preferred sequencing approach. However, accelerated introduction and uptitration are also major treatment goals. Strategy trials in treatment guidance are needed to further change practices | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Mineralocorticoid Receptor Antagonists |2 NLM | |
| 700 | 1 | |a Bonnet, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Mullens, Wilfried |e verfasserin |4 aut | |
| 700 | 1 | |a Giraldo, Clara Ines Saldarriaga |e verfasserin |4 aut | |
| 700 | 1 | |a Mežnar, Anja Zupan |e verfasserin |4 aut | |
| 700 | 1 | |a Barasa, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Tokmakova, Mariya |e verfasserin |4 aut | |
| 700 | 1 | |a Shchendrygina, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Francisco Moscoso |e verfasserin |4 aut | |
| 700 | 1 | |a Mapelli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Zemrak, Filip |e verfasserin |4 aut | |
| 700 | 1 | |a Tops, Laurens F |e verfasserin |4 aut | |
| 700 | 1 | |a Jakus, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Arian |e verfasserin |4 aut | |
| 700 | 1 | |a Bahouth, Fadel |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjseyd, Chahr-Eddine |e verfasserin |4 aut | |
| 700 | 1 | |a Salvat, Muriel |e verfasserin |4 aut | |
| 700 | 1 | |a Anselmino, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Messroghli, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Weberndörfer, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Giverts, Ilya |e verfasserin |4 aut | |
| 700 | 1 | |a Bochaton, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Courand, Pierre Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Berthelot, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Legallois, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Beauvais, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Lamblin, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Damy, Thibaud |e verfasserin |4 aut | |
| 700 | 1 | |a Girerd, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Sebbag, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Pezel, Théo |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Solal, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Rosano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Roubille, François |e verfasserin |4 aut | |
| 700 | 1 | |a Mewton, Nathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d 1999 |g 25(2023), 2 vom: 21. Feb., Seite 213-222 |w (DE-627)NLM106698575 |x 1879-0844 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:2 |g day:21 |g month:02 |g pages:213-222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ejhf.2743 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 2 |b 21 |c 02 |h 213-222 | ||